MARKETWIRE.NET

Decode Your Next Market Move

Global Industry Analysts, Inc. (GIA) launches comprehensive analysis of industry segments, market trends, growth drivers, market share, size and demand forecasts on the global Pharmaceutical Contract Manufacturing market. Market segmentation includes Product Types (API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations, and Other Product Types).

Find Out More About Regions, Brands, Dominant, Active & Niche Companies Covered in the Report

24 November 2:26 a.m., Silicon Valley, California - According to the new market research report, the global market for Pharmaceutical Contract Manufacturing is projected to grow at a CAGR of 4.6% reach US$136.5 billion by 2027, driven by increasing demand of the rapidly expanding biopharmaceutical industry. Pharmaceutical Contract Manufacturing (PCM) market is expected to witness steady growth. Increasing number of virtual companies with no production capabilities is also benefiting the PCM market. With the market gradually inching towards biopharmaceuticals, with several of such drugs being developed by start-up or smaller biotech companies who either have no or limited production capabilities is also fueling growth in pharmaceutical contract services. Even for larger pharma and biotech companies, contract manufacturing provides the benefit of additional capacity, technical resource expansion, risk aversion during demand fluctuations and geographical reach. Increasing market for generics and biosimilars also presents sizable growth prospects for the industry going forwards. Increasing geriatric patient population, growing consumption of medicines, rising healthcare expenditure, improvising healthcare infrastructure in emerging markets and mounting pressure to reduce healthcare costs are other factors driving growth in the PCM market. Growing need to achieve cost efficiencies, increasing complexity of drugs, and the requirement of advanced technologies for achieving product differentiation also drives the market.

The PCM market is expected to exhibit healthy growth in the long term, mirroring the expected positive trends in the broader pharmaceuticals market which is in turn driven by growth in the emerging markets. Governments are endeavoring to provide healthcare access and medical insurance coverage to broader section of the population, which is expected to drive absolute spending on medicines, drug products, and therapeutics, with a positive outcome for the pharmaceutical market in the near term. Furthermore, the ongoing patent expiries of blockbuster drugs, and the tide of lower-cost generics poised to come into the marketplace in the short-to-medium term is lending momentum to the global pharmaceuticals market. The robust demand for medication and therapeutics in the emerging economies, coupled with the increasing commercialization of generics and emerging technologies are anticipated to provide the thrust for the global pharmaceutical contract manufacturing market through to 2027. Against this backdrop, the global Pharmaceutical Contract Manufacturing (PCM) market is expected to witness steady growth.

Increasing number of virtual companies with no production capabilities is also benefiting the PCM market. With the market gradually inching towards biopharmaceuticals, with several of such drugs being developed by start-up or smaller biotech companies who either have no or limited production capabilities is also fuelling growth in pharmaceutical contract services. Even for larger pharma and biotech companies, contract manufacturing provides the benefit of additional capacity, technical resource expansion, and risk aversion during demand fluctuations and geographical reach. Increasing market for generics and biosimilars also presents sizable growth prospects for the industry going forwards. Increasing geriatric patient population, growing consumption of medicines, rising healthcare expenditure, improvising healthcare infrastructure in emerging markets and mounting pressure to reduce healthcare costs are other factors driving growth in the PCM market. Growing need to achieve cost efficiencies, increasing complexity of drugs, and the requirement of advanced technologies for achieving product differentiation also drives the market.

Research Methodology
This latest edition of the research study is conducted and published by Global Industry Analysts, Inc., in close collaboration with senior executives in the industry driving strategy, business development, marketing, sales, product management, technology and operations. All analysis and findings published in the report are based on validated engagements from a total executive pool size of 3679. Among this pool, 662 direct interactions with domain experts were carried out via our proprietary market research platform, MarketGlass. Among the 112 unique participations, a total of 51 validated responses were received as part of this report's primary research outreach program. We are unique in the industry to provide our clients with the validated list executive engagements and the complete project data stack.

Key Competitors Covered in the Report -
Boehringer Ingelheim International GmbH
Baxter International, Inc.
Hospira, Inc.
Albany Molecular Research, Inc.
Catalent Pharma Solutions
Ajinomoto Bio-Pharma Services
Cobra Biologics
Dishman Group
Aenova Holding GmbH
Alcami Corporation
CordenPharma International
Famar Health Care Services

Segments Covered in the Report -
Product Type (API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations, Other Product Types)
Application (Pharmaceutical, Biopharmaceutical)
End-Use (Sterile, Non-Sterile)

Geographies Analyzed in the Report -
World
USA
Canada
Japan
China
Europe
France
Germany
Italy
UK
Rest of Europe
Asia-Pacific
India
Rest of Asia-Pacific
Rest of World.

View Executive Engagement Dashboards, COVID Impact Questionnaires & Get Complimentary Access to Methodology & Full-Text Secondary Sources

For enquiries e-mail us at sales@strategyR.com .

For cutting edge analyst reviews on top industries, follow us on Twitter and connect with us on LinkedIn

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) (www.strategyr.com) is the world`s only influencer driven AI powered market research company. Serving more than 41,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for 33 years, offering the widest coverage of topics, geographic markets, competitive brands, and companies profiled.

Contact Us:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
Email: sales@StrategyR.com